FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic

The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.

May 1, 2024 - 00:10
0
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
Read More